Skip to main content

Xavier Thomas MD

Xavier Thomas is in charge of the management and treatment of adult patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) in the Department of Hematology at the Lyon-Sud Hospital (France). He is member of the American Society of Hematology (ASH), American Society of Clinical Oncology (ASCO), American Association for Cancer Research (AACR) and European Hematology Association (EHA). He is actively involved in the Group for Research in Adult Acute Lymphoblastic Leukemia (GRAALL) and the Acute Leukemia French Association (ALFA). He has published more than 400 peer-reviewed papers and has served as a referee for several journals, including Blood, Leukemia, The Lancet, The New England Journal of Medicine, Leukemia & Lymphoma, and Cancer.

Latest contributions from Xavier Thomas

14-03-2017 | Leukemia | Editorial | Article

FMS-like tyrosine kinase 3 (FLT3)-inhibition in FLT3 mutated acute myeloid leukemia: A promising approach

Advisory Board Member Xavier Thomas discusses the potential of FLT3 inhibitors for the treatment of acute myeloid leukemia.